Register entry
- Registered sites
- 1
- Active NDC listings
- 73
- Labeller names
- 6
- Live patents
- 0
- Countries
- 1
- Base
- Germany
Authorisation
Registered operations
Analytical testing1Active ingredient (API) manufacture1Labelling1Finished drug manufacture1Packaging1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Excella GmbH & Co. KG | Nuernberger Str. 12, Feucht, Bavaria 90537, Germany (DEU) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3000242652329809800 |
Catalogue
Drug listings by form and route
7373 active NDC listings: 51 bulk ingredient, 22 human prescription drug. By marketing category: BULK INGREDIENT 41, DRUG FOR FURTHER PROCESSING 22, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING 10.
| Dosage form | NDCs |
|---|---|
| powder | 48 |
| capsule | 13 |
| tablet, film coated | 6 |
| injection, solution | 2 |
| tablet | 2 |
| injection | 1 |
| kit | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| excella gmbh & co. kg | 68 |
| excella gmbh & co kg | 1 |
| excella gmbh & co. kg | 1 |
| excella gmbh & co.kg | 1 |
| excella gmbh &co.kg | 1 |
| excella gmbh co. kg | 1 |
Catalogue
Marketed products
73| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | ALECTINIB HYDROCHLORIDE | capsule | 46014-0130DRUG FOR FURTHER PROCESSING |
| - | Acyclovir Sodium | powder | 46014-1019BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Adapalene | powder | 46014-1098BULK INGREDIENT |
| - | Anastrozole | powder | 46014-1009BULK INGREDIENT |
| - | Anastrozole | powder | 46014-1160BULK INGREDIENT |
| - | Anastrozole | powder | 46014-1161BULK INGREDIENT |
| - | Baclofen | powder | 46014-1035BULK INGREDIENT |
| - | Baclofen | powder | 46014-1124BULK INGREDIENT |
| - | Baclofen(R) | powder | 46014-1014BULK INGREDIENT |
| - | Bicalutamide | powder | 46014-1111BULK INGREDIENT |
| - | Bicalutaminde milled | powder | 46014-1163BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Bupivacaine Hydrochloride monohydrate | powder | 46014-1113BULK INGREDIENT |
| - | Buspirone HCl | powder | 46014-1068BULK INGREDIENT |
| - | Buspirone Hydrochloride sieved | powder | 46014-1480BULK INGREDIENT |
| - | Cevimeline Hydrochloride | powder | 46014-1002BULK INGREDIENT |
| - | Clomiphene citrate | powder | 46014-1122BULK INGREDIENT |
| - | Deferoxamine mesylate | powder | 46014-1003BULK INGREDIENT |
| - | Deferoxamine mesylate | powder | 46014-1127BULK INGREDIENT |
| - | Deracoxib | powder | 46014-1082BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Deracoxib milled | powder | 46014-1170BULK INGREDIENT |
| - | Doxazosin mesylate | powder | 46014-1001BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | EMTRICITABINE | capsule | 46014-6010DRUG FOR FURTHER PROCESSING |
| - | Eplerenone | powder | 46014-1102BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Firocoxib | powder | 46014-1012BULK INGREDIENT |
| - | Firocoxib | powder | 46014-1112BULK INGREDIENT |
| - | Ganciclovir Sodium | injection | 46014-1054BULK INGREDIENT |
| - | Haloperidol | powder | 46014-1114BULK INGREDIENT |
| - | Lanthanum Carbonate Hydrated | powder | 46014-1126BULK INGREDIENT |
| - | Levothroxine sodium | powder | 46014-1013BULK INGREDIENT |
| - | Levothyroxine Sodium | powder | 46014-1083BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Methotrexate | powder | 46014-1005BULK INGREDIENT |
| - | Methotrexate | powder | 46014-1023BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Methotrexate | powder | 46014-1133BULK INGREDIENT |
| - | Methotrexate Disodium | powder | 46014-1500BULK INGREDIENT |
| - | Methotrexate Disodium Salt | powder | 46014-1119BULK INGREDIENT |
| - | Mycophenolate Mofetil | powder | 46014-1123BULK INGREDIENT |
| - | Paroxetine Mesylate | powder | 46014-1097BULK INGREDIENT |
| - | Paroxetine Mesylate | powder | 46014-1125BULK INGREDIENT |
| - | Pirenzepine Monohydrate | powder | 46014-1210BULK INGREDIENT |
| - | Relugolix | powder | 46014-1130BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Ropivacaine Hydrochloride | injection, solution | 46014-1470BULK INGREDIENT |
| - | Ropivacaine hydrochloride | injection, solution | 46014-1058BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Selexipag | capsule | 46014-0602DRUG FOR FURTHER PROCESSING |
| - | Selexipag | capsule | 46014-0608DRUG FOR FURTHER PROCESSING |
| - | Selexipag | capsule | 46014-0621DRUG FOR FURTHER PROCESSING |
| - | Selexipag | kit | 46014-6280DRUG FOR FURTHER PROCESSING |
| - | TRYVIO | capsule | 46014-8012DRUG FOR FURTHER PROCESSING |
| - | Talazoparib | powder | 46014-1140BULK INGREDIENT |
| - | Tamoxifen Citrate | powder | 46014-1190BULK INGREDIENT |
| - | Tamoxifen Citrate | powder | 46014-1200BULK INGREDIENT |
| - | Tamoxifen citrate | powder | 46014-1015BULK INGREDIENT |
| - | Tamoxifen citrate | powder | 46014-1180BULK INGREDIENT |
| - | Temozolomide | powder | 46014-1121BULK INGREDIENT |
| - | Temozolomide | powder | 46014-1450BULK INGREDIENT |
| - | Temozolomide | powder | 46014-1460BULK INGREDIENT |
| - | Timolol maleate | powder | 46014-1059BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Timolol maleate | powder | 46014-1490BULK INGREDIENT |
| - | Timolol(S)Base Hemihydrate | powder | 46014-1159BULK INGREDIENT |
| - | UPTRAVI | capsule | 46014-6040DRUG FOR FURTHER PROCESSING |
| - | UPTRAVI | capsule | 46014-6060DRUG FOR FURTHER PROCESSING |
| - | UPTRAVI | capsule | 46014-6100DRUG FOR FURTHER PROCESSING |
| - | UPTRAVI | capsule | 46014-6120DRUG FOR FURTHER PROCESSING |
| - | UPTRAVI | capsule | 46014-6140DRUG FOR FURTHER PROCESSING |
| - | UPTRAVI | capsule | 46014-6160DRUG FOR FURTHER PROCESSING |
| - | azacitidine | tablet, film coated | 46014-7200DRUG FOR FURTHER PROCESSING |
| - | azacitidine | tablet, film coated | 46014-7300DRUG FOR FURTHER PROCESSING |
| - | busulfan | tablet, film coated | 46014-6202DRUG FOR FURTHER PROCESSING |
| - | capecitabine | tablet, film coated | 46014-4751DRUG FOR FURTHER PROCESSING |
| - | chlorambucil | tablet, film coated | 46014-6102DRUG FOR FURTHER PROCESSING |
| - | macitentan | tablet, film coated | 46014-5010DRUG FOR FURTHER PROCESSING |
| - | neratinib | tablet | 46014-2400DRUG FOR FURTHER PROCESSING |
| - | paroxetine | capsule | 46014-9076DRUG FOR FURTHER PROCESSING |
| - | thioguanine | tablet | 46014-6302DRUG FOR FURTHER PROCESSING |
Compare
Comparable companies in Germany
- PEKANA Naturheilmittel GmbH1 site · 62 NDC
- Grillo Zinc Powder GmbH1 site · 22 NDC
- Nestmann Pharma GMBH1 site · 18 NDC
- Rottendorf Pharma GmbH1 site · 17 NDC
- Arevipharma GmbH1 site · 13 NDC
- Chemische Fabrik Berg GmbH1 site · 13 NDC
- Eckert & Ziegler Radiopharma GmbH1 site · 11 NDC
- Heraeus Precious Metals GmbH Co KG1 site · 10 NDC
- Solupharm Pharmazeutische Erzeugnisse GmbH1 site · 10 NDC
- BSV Bioscience GmbH1 site · 9 NDC
Enquiry
Common questions
- Is Excella GmbH & Co. KG FDA approved?
- Excella GmbH & Co. KG holds 1 FDA-registered establishment in Germany. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Excella GmbH & Co. KG's drugs manufactured?
- The FDA register lists Feucht. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Excella GmbH & Co. KG make?
- 73 products are listed under Excella GmbH & Co. KG in the openFDA NDC Directory, most often as powder; capsule; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.